A doctor, bariatric surgeon and professor say that treatments other than weight-loss drugs are needed to fix the obesity ...
A recent meta-analysis of 69 clinical trials found the risk for ischemic optic neuropathy from GLP-1 therapy is too low to be ...
Two new studies identified additional benefits of medications like semaglutide—the active ingredient in Novo Nordisk's ...
As Ozempic keeps flying off the shelves, more and more people are taking the drug into their own hands by "microdosing" it.
Semaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...
Reports of pulmonary aspiration and difficulties in diagnosing gastrointestinal complications in the perioperative period have highlighted the need for clear clinical guidance to manage these patients ...
The holidays are a time known for feasting on delicious food, but that might not be possible for people taking weight-loss drugs.
The use of GLP-1s is linked to improved inflammatory bowel disease outcomes in patients with concomitant inflammatory bowel ...
The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...
A study reveals that weight loss can lead to significant healthcare savings, with 7% savings for a 5% BMI reduction and 30% ...
After this, the situation will be reviewed by Nice, who will provide further guidance on the rollout. Mounjaro is a ...
A study finds that anti-obesity medications may help reduce alcohol consumption, with nearly half of participants in weight ...